Opus Genetics IRD Research And Development Expense Including Acquired In Process Cost
Research And Development Expense Including Acquired In Process Cost at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept ird:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost.
The official record: Opus Genetics’s 10-K, filed March 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's research and development expense including acquired in process cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's research and development expense including acquired in process cost?
- Opus Genetics (IRD) reported research and development expense including acquired in process cost of $0 in Q4 2025.
- How has Opus Genetics's research and development expense including acquired in process cost changed year-over-year?
- Opus Genetics's research and development expense including acquired in process cost decreased by 100.0% year-over-year, from $7M to $0.
- What does research and development expense including acquired in process cost mean?
- Includes all costs associated with the research and development of product candidates, including the acquisition of in-process technology. This is the primary driver of cash burn for clinical-stage biopharma companies. It reflects the company's investment in its pipeline and future commercial potential.